Nature medicine
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study.
2026
-
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration..
32:2083-2095.
2026
-
Deleterious coding variation associated with autism is shared across ancestries..
32:1519-1529.
2026
-
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks..
32:1085-1094.
2026
-
Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study..
32:527-544.
2026
-
Academia Europaea's guidelines for the visualization of clinical outcomes..
31:3976-3980.
2025
-
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial..
32:353-361.
2025
-
Publisher Correction: Academia Europaea's guidelines for the visualization of clinical outcomes..
31:-.
2025
-
Physical activity as a modifiable risk factor in preclinical Alzheimer's disease..
31:4075-4083.
2025
-
Strengthening Africa's brain health and economic resilience..
31:2506-2517.
2025
-
Resilience and brain health in global populations..
31:2518-2531.
2025
-
Reevaluating the role of education on cognitive decline and brain aging in longitudinal cohorts across 33 Western countries..
31:2967-2976.
2025
-
Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025..
31:3889-3898.
2025
-
Polygenic prediction of body mass index and obesity through the life course and across ancestries..
31:3151-3168.
2025
-
Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging..
31:2578-2589.
2025
-
Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases..
31:2567-2577.
2025
-
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging..
31:2556-2566.
2025
-
The exposome of healthy and accelerated aging across 40 countries..
31:3089-3100.
2025
-
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma..
31:1183-1194.
2025
-
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease..
31:1592-1603.
2025
-
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease..
31:2044-2053.
2025
-
Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial..
31:1586-1591.
2025
-
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia..
31:1267-1275.
2025
-
Toward a biological definition of neuronal and glial synucleinopathies..
31:396-408.
2025
-
Cytokine-mediated CAR T therapy resistance in AML..
30:3697-3708.
2024
-
Brain aging patterns in a large and diverse cohort of 49,482 individuals..
30:3015-3026.
2024
-
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial..
30:-.
2024
-
Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease..
30:3096-3097.
2024
-
AI-based differential diagnosis of dementia etiologies on multimodal data..
30:2977-2989.
2024
-
Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease..
30:2990-3003.
2024
-
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial..
30:2605-2612.
2024
-
Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease..
30:-.
2024
-
Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risks..
30:1711-1721.
2024
-
APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease..
30:1284-1291.
2024
-
Tackling heat-related mortality in aging populations..
30:1247-1248.
2024
-
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests..
30:1085-1095.
2024
-
Validation of biomarkers of aging..
30:360-372.
2024
-
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial..
29:2481-2488.
2023
-
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial..
29:2358-2365.
2023
-
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease..
29:1979-1988.
2023
-
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease..
29:1954-1963.
2023
-
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results..
29:1710-1717.
2023
-
Clonal hematopoiesis is associated with protection from Alzheimer's disease..
29:1662-1670.
2023
-
Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man..
29:1243-1252.
2023
-
Organ-specific aging and the risk of chronic diseases..
29:1068-1069.
2023
-
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial..
29:880-887.
2023
-
Implementing clinical trial data sharing requires training a new generation of biomedical researchers..
29:298-301.
2023
-
Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit..
29:2526-2534.
2023
-
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies..
28:2547-2554.
2022
-
Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline..
28:2381-2387.
2022
-
Cellular senescence and senolytics: the path to the clinic..
28:1556-1568.
2022
-
An ethical plan for including forcibly displaced persons in omics and digital technology research..
28:1116-1120.
2022
-
A multisystem, cardio-renal investigation of post-COVID-19 illness..
28:1303-1313.
2022
-
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial..
27:1954-1960.
2021
-
Why aducanumab is important..
27:-.
2021
-
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease..
27:1187-1196.
2021
-
Direct-to-consumer personal genomic tests need better regulation..
27:940-943.
2021
-
SARS-CoV-2 infection of the oral cavity and saliva..
27:892-903.
2021
-
Post-acute COVID-19 syndrome..
27:601-615.
2021
-
Recommendations for measuring HIV reservoir size in cure-directed clinical trials..
26:1339-1350.
2020
-
Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease..
26:-.
2020
-
Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation..
26:769-780.
2020
-
Integrated single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection..
26:511-518.
2020
-
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease..
26:398-407.
2020
-
Chronic inflammation in the etiology of disease across the life span..
25:1822-1832.
2019
-
Undulating changes in human plasma proteome profiles across the lifespan..
25:1843-1850.
2019
-
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report..
25:1680-1683.
2019
-
Neurogenetic contributions to amyloid beta and tau spreading in the human cortex..
24:1910-1918.
2018
-
Senolytics improve physical function and increase lifespan in old age..
24:1246-1256.
2018
-
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease..
24:931-938.
2018
-
Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy..
24:427-437.
2018
-
IRF3 and type I interferons fuel a fatal response to myocardial infarction..
23:1481-1487.
2017
-
Gpr124 is essential for blood-brain barrier integrity in central nervous system disease..
23:450-460.
2017
-
Caspase-2 and tau-a toxic partnership?.
22:1207-1208.
2016
-
A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance..
22:421-6.
2016
-
PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically..
22:37-45.
2015
-
A technique for in vivo mapping of myocardial creatine kinase metabolism..
20:209-14.
2014
-
Translational strategies and challenges in regenerative medicine..
20:814-21.
2014
-
Ironing out tau's role in parkinsonism..
18:197-8.
2012
-
Finding a sirtuin truth in Huntington's disease..
18:24-6.
2012
-
Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death..
17:692-9.
2011
-
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets..
18:153-8.
2011
-
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease..
16:998-1000.
2010
-
Memantine strikes the perfect balance..
15:1355-6.
2009
-
Getting a handle on Huntington's disease: silencing neurodegeneration..
15:252-3.
2009
-
NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF..
13:62-9.
2006
-
Taming the clot-buster tPA..
12:993-4.
2006
-
Role of matrix metalloproteinases in delayed cortical responses after stroke..
12:441-5.
2006
-
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo..
12:856-61.
2006
-
Regulation of lung injury and repair by Toll-like receptors and hyaluronan..
11:1173-9.
2005
-
Targeting toxic proteins for turnover..
11:1052-3.
2005
-
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production..
11:545-50.
2005
-
Inflammation takes on Alzheimer disease..
8:936-8.
2002
-
CREB family transcription factors inhibit neuronal suicide..
8:450-1.
2002
-
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease..
7:1144-50.
2001
-
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease..
5:1403-9.
1999
-
Regenerating functional myocardium: improved performance after skeletal myoblast transplantation..
4:929-33.
1998
-
An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow..
4:333-5.
1998
-
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia..
3:1089-95.
1997
-
Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans..
3:571-4.
1997
-
Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A..
3:421-8.
1997
Identity
International Standard Serial Number (ISSN)